

# Exactus, Inc.

13:07 15 Aug 2019

## Exactus executes its growth strategy following Oregon hemp farm acquisition

Exactus Inc (OTCMKTS:EXDI) updated investors on a busy second quarter that saw the company integrate a new acquisition of 200-acres of Oregon hemp farms.

The Florida-based healthcare company is pursuing opportunities in hemp-derived cannabidiol (CBD) products.

In April 2019, Exactus initiated operations on two 100-acre industrial hemp farms in Oregon after acquiring a majority interest in March.

**READ:** Exactus expands with acquisition of Green Goddess Extracts, a highly regarded Florida contract manufacturer and formulator of hemp and vape products

Emiliano Aloï, the company's president, said that the company has procured quality supply and established manufacturing operations and distribution channels to sell its products.

"Our business model is differentiated from most competitors in the CBD market in that we have full traceability from our seed through our own product supply chain ensuring that our customers get a quality product with full knowledge about where their product came from," said Aloï in a statement.

"In an emerging growth market, we place a great importance in maintaining the highest standards."

Following the Oregon acquisition, the company is building its presence in the US through a more recent deal with Green Goddess Extracts, a highly regarded Florida contract manufacturer and formulator of hemp and vape products which distributes a premium line of high-quality hemp products sold through distributors and online. Exactus announced the deal in early August.

For the three month-period ended June 30, 2019 the healthcare company reported nearly US\$140,000 in revenue as it begins to ship product to customers. The net loss was US\$1.1 million or \$0.03 per share.

Financial results for the period represent the very early stages of a "significant" opportunity, Exactus told investors in a release.

Shares of Exactus nudged 1.5% higher on Thursday at US\$1.40.

Contact Angela at [angela@proactiveinvestors.com](mailto:angela@proactiveinvestors.com)

Follow her on Twitter @AHarmantas

**Price:** 0.077

**Market Cap:** \$4.1 m

### 1 Year Share Price Graph



December 2019 May 2020 December 20

### Share Information

**Code:** EXDI

**Listing:** OTCQB

<b>52 week</b>	<b>High</b>	<b>Low</b>
	0.63	0.04

**Sector:** Pharma & Biotech

**Website:** [www.exactusinc.com](http://www.exactusinc.com)

### Company Synopsis:

*Exactus, Inc. , is a healthcare company pursuing opportunities in two distinct business segments, Hemp derived, Cannabidiol, which is more commonly referred to as CBD. Industrial hemp is a type of cannabis, defined by the federal government as having THC (tetrahydrocannabinol) content of 0.3 percent or less. THC is the psychoactive compound found in cannabis. The company is also developing point of care diagnostics.*

[action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Exactus, Inc. named herein, including the promotion by the Company of Exactus, Inc. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).